Physician profile
John M Wise
NPI 1477556496
$10,852.65
in general payments reported to CMS, 2019-2025
43 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,916 · 2021: $2,515 · 2022: $1,640 · 2023: $1,461 · 2024: $1,260 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,873 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.38 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,794.64 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Viiv Healthcare Company | $1,067.53 | 2020-2025 | Apretude, Dovato |
| Pfizer INC. | $1,061.29 | 2020-2025 | |
| Lilly USA, LLC | $883.31 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $637.85 | 2019-2025 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $559.59 | 2019-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $538.23 | 2019-2025 | |
| Novo Nordisk INC | $415.31 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bausch Health US, LLC | $379.75 | 2019-2025 | Wellbutrin, Aplenzin |
| Allergan, INC. | $372.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.11 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $292.73 | 2022 | |
| Astellas Pharma US INC | $292.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $285.63 | 2020-2023 | Dificid, Pifeltro, Delstrigo |
| Idorsia Pharmaceuticals US INC | $244.26 | 2022-2025 | Quviviq, Quviviq |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.